GITNUXSOFTWARE ADVICE
International MarketsTop 10 Best Market Access Consulting Services of 2026
Top 10 market access consulting services ranked by criteria for pharma payers and providers, with side-by-side notes on RTI Health Solutions.
How we ranked these tools
Core product claims cross-referenced against official documentation, changelogs, and independent technical reviews.
Analyzed video reviews and hundreds of written evaluations to capture real-world user experiences with each tool.
AI persona simulations modeled how different user types would experience each tool across common use cases and workflows.
Final rankings reviewed and approved by our editorial team with authority to override AI-generated scores based on domain expertise.
Score: Features 40% · Ease 30% · Value 30%
Gitnux may earn a commission through links on this page — this does not influence rankings. Editorial policy
RTI Health Solutions is the best fit when payer pathway risk and evidence planning need external experts who can translate that thinking into payer-ready evidence, whereas Charles River Associates suits teams needing analytically rigorous reimbursement strategy across multiple payers, and if you need a cheaper entry slot, Simon-Kucher & Partners is a strong alternative for end-to-end market access artifacts tied to execution.
Editor’s top 3 picks
Three quick recommendations before you dive into the full comparison below — each one leads on a different dimension.
RTI Health Solutions
Evidence generation plan development that ties payer evidence requirements to draft dossier content and study concepts.
Built for fits when payer pathway risk and evidence planning must be handled by external experts..
Putnam Associates
Editor pickPayer evidence requirements mapping that traces each payer expectation to specific evidence gaps and dossier implications.
Built for fits when pharma teams need reimbursement pathway decisions translated into payer-ready evidence plans..
Charles River Associates
Editor pickEconomics-first reimbursement and pricing strategy work that ties payer evidence needs to concrete dossier and submission decisions.
Built for fits when pharma teams need analytically rigorous reimbursement strategy and evidence planning across multiple payers..
Comparison Table
RTI Health Solutions
specialistHealth economics and outcomes research organization providing market access evidence generation and consulting.
Evidence generation plan development that ties payer evidence requirements to draft dossier content and study concepts.
RTI Health Solutions is most effective for teams that need structured market access strategy backed by reimbursement feasibility logic and evidence planning. Payer landscape assessment and reimbursement pathway analysis map payer decision points to the proof requirements that later feed value dossier drafting and HTA submission packages. The firm’s work style is geared toward stakeholder mapping and payer engagement inputs that can be converted into an actionable launch plan and submission narrative.
A tradeoff appears when internal teams expect automation-first workflows or self-serve configuration, because RTI Health Solutions is consultative and deliverable-led rather than tool-led. RTI Health Solutions fits usage situations where a payer-driven question needs expert interpretation and synthesis, such as correcting pathway assumptions before primary research begins or tightening the evidence package before submission development.
- +Clear link from reimbursement pathway logic to evidence plan deliverables
- +Strong payer engagement support for stakeholder mapping and interview synthesis
- +Experienced HEOR-to-submission translation for HTA and reimbursement packages
- +Consistent documentation that supports cross-functional review cycles
- –Consulting-led delivery leaves limited automation surface for self-serve teams
- –Requires active sponsor input for scoping payer evidence generation assumptions
- –Best results depend on timely access to internal clinical and commercial data
- –Less suitable for teams seeking an API-first workflow system
Market access strategy teams
Early payer pathway scoping
Fewer pathway assumption changes
HEOR and biostats leads
Evidence plan and endpoints alignment
More focused study execution
Show 2 more scenarios
Pricing and reimbursement teams
Value dossier narrative building
More coherent reimbursement story
Builds a value dossier that matches reimbursement submission logic and payer decision criteria.
Clinical development teams
Comparative evidence gap definition
Clearer evidence generation priorities
Identifies evidence gaps and translates them into study concepts aligned to payer expectations.
Best for: Fits when payer pathway risk and evidence planning must be handled by external experts.
Putnam Associates
specialistLife sciences strategy consulting firm with market access and commercial strategy capabilities.
Payer evidence requirements mapping that traces each payer expectation to specific evidence gaps and dossier implications.
Putnam Associates is a strong fit for teams coordinating payer evidence requirements, payer engagement plans, and reimbursement submission materials across multiple geographies or payer types. The deliverables typically emphasize reimbursement pathway analysis and payer evidence requirements mapping rather than generic competitive benchmarking. Analysts convert payer policy signals into concrete implications for evidence generation plans and value dossier content. This creates usable artifacts for internal governance and external discussions with payers, HTA bodies, and advisory stakeholders.
A key tradeoff is that the work is consulting-led, so it depends on timely access to product data, protocol constraints, and commercial assumptions from the client. The most effective usage situation is early in the launch planning cycle, when pathway constraints and payer expectation gaps can be resolved before study timelines harden. Teams that enter late in the process often find that evidence generation planning and dossier shaping require rapid rework of upstream assumptions.
- +Reimbursement pathway analysis maps payer policy to execution decisions
- +Deliverables connect payer evidence requirements to evidence generation plans
- +Strong coverage policy and formulary positioning support for launch timing
- +Clear stakeholder mapping for payer engagement and negotiation prep
- –Consulting-led delivery requires client-provided data and timely reviews
- –Automation depth is limited compared with software-first market access tooling
- –Late-stage starts can force rework of evidence and dossier assumptions
Market access strategy teams
Build global payer evidence plan
Gaps ranked by payer impact
Medical affairs leaders
Align comparative evidence to dossiers
Study objectives tied to payers
Show 1 more scenario
Commercial and pricing teams
Prepare payer engagement strategy
Negotiation themes with payer logic
Synthesizes coverage policy signals into stakeholder mapping and negotiation preparation materials.
Best for: Fits when pharma teams need reimbursement pathway decisions translated into payer-ready evidence plans.
Charles River Associates
enterprise_vendorConsulting firm offering life sciences advisory including market access, pricing, and health economics.
Economics-first reimbursement and pricing strategy work that ties payer evidence needs to concrete dossier and submission decisions.
Charles River Associates is a fit for teams that need economics modeling rigor and payers- and systems-level reasoning, not just market narrative. Engagements commonly produce clear reimbursement pathway artifacts, payer landscape assessments, and evidence generation plans that link evidence needs to dossier and payer submission activities. Analysts also support formulary positioning choices through coverage policy analysis and scenario framing for launch sequences.
A tradeoff is that CRA delivery style prioritizes analytical depth over rapid turnaround for highly iterative workshops. It performs best when a team can provide access to internal clinical and commercial inputs early and commit to structured stakeholder sessions tied to decision milestones.
- +Economics-driven reasoning that strengthens payer negotiation positions
- +Decision-grade reimbursement pathway outputs for cross-functional alignment
- +Evidence generation roadmaps mapped to payer submission requirements
- +Experienced facilitation for payer engagement strategy planning
- –Not optimized for rapid, highly iterative workshop cycles
- –Stakeholder availability delays can slow evidence-plan finalization
- –Requires strong client inputs to keep analyses decision-relevant
- –Less suited to lightweight desk research without modeling depth
Market access strategy teams
Design payer evidence generation plan
Aligned evidence roadmap
Commercial leadership
Set launch pricing and access approach
Consistent launch positioning
Show 2 more scenarios
Medical affairs
Plan comparative and real-world evidence
Prioritized evidence program
Build evidence generation guidance for payer-facing claims and study design prioritization.
Regulatory and HEOR
Support submission pathway readiness
Submission-ready evidence logic
Map evidence and analytics needs to HTA submission and reimbursement preparation workflows.
Best for: Fits when pharma teams need analytically rigorous reimbursement strategy and evidence planning across multiple payers.
ZS
enterprise_vendorSales, marketing, and strategy consulting firm with a dedicated market access practice for life sciences.
Global value dossier development that aligns payer evidence requirements to dossier content across multiple submission timelines.
ZS provides market access consulting for pharma and life sciences, with a services-heavy delivery model anchored in payer strategy, evidence planning, and reimbursement execution support. The firm routinely maps payer coverage and clinical expectations into structured pathway recommendations that connect dossier content to payer evidence requirements.
ZS also supports global value dossier development and payer engagement planning across jurisdictions where evidence expectations differ by market. Delivery emphasis centers on synthesis of competitive and payer landscape inputs into actionable launch and submission workstreams, rather than on building client-facing analytics products.
- +Structured payer landscape assessments that translate into clear reimbursement pathway actions
- +Evidence generation planning tied to payer evidence requirements for submissions and negotiations
- +Global value dossier support with consistent messaging across multi-country market access workstreams
- +Cross-functional market access launch planning that connects strategy to execution tasks
- –Service-led delivery can reduce self-serve control for teams needing hands-on tooling
- –Automation depth and API surface are not the focus for client integration
- –Governance tooling like RBAC and audit log controls are not central to the offering
- –Effort can concentrate on analyst review, which raises lead-time for iterative stakeholder cycles
Best for: Fits when global pharma teams need evidence-led payer strategy delivered through end-to-end market access workstreams.
Simon-Kucher & Partners
enterprise_vendorGlobal strategy consulting firm specializing in pricing and market access for pharmaceutical clients.
Evidence generation planning that maps payer evidence requirements directly to dossier structure and submission-ready outputs.
Simon-Kucher & Partners runs market access consulting engagements that translate payer and HTA requirements into a measurable reimbursement path. Teams get payer landscape assessment, evidence generation planning, and value dossier support for both global and country submission workflows.
Delivery emphasizes payer evidence requirements mapping to monetization and access scenarios, including budget impact model inputs and launch planning. For pharma and life sciences teams, the work connects reimbursement submission artifacts with payer engagement and stakeholder strategy rather than treating pricing documents as stand-alone deliverables.
- +Connects reimbursement submission content to payer evidence requirements and pathway logic
- +Produces structured value dossier materials for global and local payer contexts
- +Builds budget impact model assumptions around access scenarios and launch constraints
- +Supports payer engagement planning with stakeholder mapping and KOL interview inputs
- –Requires tight internal access to clinical and operational inputs for evidence planning
- –Automation and API surfaces are not a native part of the service delivery
- –Governance and review cycles can extend timelines for iterative payer feedback loops
- –Less suited to teams needing tooling for real-time payer intelligence monitoring
Best for: Fits when pharma teams need end-to-end market access strategy artifacts linked to reimbursement pathway execution.
Deloitte
enterprise_vendorBig Four professional services firm offering life sciences market access and pricing consulting.
Payer and HTA evidence requirements mapping built to translate into a structured evidence generation plan for submissions and payer reviews.
Deloitte is a market access consulting provider built for pharma and life sciences teams that need end-to-end payer strategy and execution support across complex geographies. Its engagements typically cover reimbursement pathway analysis, evidence requirements mapping, and stakeholder and payer engagement planning that aligns with HTA and payer review timelines.
Deloitte also supports decision-ready deliverables such as value dossier structuring and evidence generation planning when internal teams need external analytic and project governance. For teams with heavy cross-functional dependencies, Deloitte’s consulting delivery model is strong at coordinating medical, HEOR, and commercial inputs into payer-facing materials.
- +Integrated reimbursement pathway analysis with payer and HTA evidence requirement mapping
- +Strong stakeholder mapping and payer engagement planning for structured advocacy
- +Consulting delivery model supports complex global submissions coordination
- +Clear linkage from evidence generation plans to payer evidence needs
- –Less suited for teams needing self-serve automation without consulting work
- –Requires detailed internal input to keep payer assumptions consistent across markets
- –Governance and review cycles can extend timelines for iterative strategy changes
- –Limited fit for narrow, single-asset projects without broader launch context
Best for: Fits when pharma teams need consulting-led market access strategy and evidence planning across multiple payer environments.
Certara
enterprise_vendorBiosimulation and drug development services company with market access and HEOR consulting.
Traceable evidence generation plan mapping that ties payer evidence requirements to specific study outputs and dossier sections.
Certara is a market access consulting provider that combines payer-focused strategy work with analytic capabilities grounded in pharma drug development methods. The firm supports reimbursement pathway analysis, value dossier preparation, and evidence generation planning using structured stakeholder inputs and study-ready evidence.
Certara also brings implementation support for internal planning, aligning market access deliverables with submission expectations and payer evidence requirements across regions. Delivery quality is strongest when engagement needs both strategic recommendations and traceable evidence logic across dossiers and payer communications.
- +Evidence planning links payer evidence requirements to dossier inputs
- +Structured payer landscape assessment supports regional reimbursement pathway choices
- +Experience across HTA-style evidence formats strengthens submission readiness
- +Consulting workflow supports cross-functional alignment with clinical teams
- –Engagements require high internal data availability to reach dossier-grade outputs
- –Automation depth depends on client tooling and integration choices
- –Governance artifacts like RBAC and audit log patterns are not packaged as standard software
- –Timelines can stretch when payer assumptions need iterative rework
Best for: Fits when pharma teams need traceable evidence logic across payer engagement and dossier deliverables.
LEK Consulting
enterprise_vendorGlobal strategy consulting firm with a life sciences practice covering market access and commercial strategy.
Payer evidence requirements mapping that ties reimbursement pathway decisions to an actionable evidence generation plan.
LEK Consulting delivers market access consulting grounded in payer landscape assessment and reimbursement pathway analysis for pharma and life sciences teams. Its work emphasizes payer evidence requirements, from pathway design through evidence generation planning and launch readiness.
The consultancy’s output typically targets decision workflows used in pricing and reimbursement, HTA submission support, and payer engagement materials. Delivery quality is shaped by its strategy-to-execution approach across global and country-level market access decisions.
- +Strong payer landscape assessment outputs aligned to reimbursement pathway steps
- +Evidence generation plan deliverables connect data needs to payer evidence expectations
- +Clear stakeholder mapping artifacts for payer engagement and KOL interview preparation
- +Structured support for HTA submission and reimbursement submission materials
- –Deliverables often require internal teams to implement timelines and data collection
- –Less operational guidance for coding and billing assessments than evidence and pathway work
- –Automation and API surface are not part of the engagement deliverables
Best for: Fits when global and country teams need payer-informed strategy that converts into evidence plans.
Analysis Group
enterprise_vendorEconomics consulting firm with a health sciences practice providing market access and HEOR support.
Reimbursement pathway analysis that links payer evidence requirements to a sequenced evidence generation plan for submissions.
Analysis Group delivers market access consulting work for pharma and life sciences teams focused on reimbursement and payer decision making. The firm pairs payer landscape assessment with reimbursement pathway analysis and HTA-informed evidence planning across major markets.
Deliverables typically include budget impact modeling, value dossier support for global submissions, and payer engagement strategy inputs built around evidence requirements. Engagements also cover comparative evidence planning and practical launch sequencing for pricing and coverage milestones.
- +Evidence planning grounded in payer and HTA evidence requirements
- +Budget impact modeling support tied to reimbursement pathway assumptions
- +Comparative evidence and CER inputs for value dossier narratives
- +Clear stakeholder mapping outputs for payer engagement planning
- –Delivery depends on client-provided data quality and access timelines
- –Automation and API surface is not a native capability for request workflow
- –Governance artifacts like RBAC and audit logs are not a published focus
- –Model iteration cycles require structured change management from teams
Best for: Fits when global pharma teams need reimbursement strategy and evidence planning across multiple payer and HTA contexts.
Health Advances
specialistHealthcare strategy consulting firm advising on market access, reimbursement, and commercialization.
Dossier-aligned evidence generation planning that converts payer evidence requirements into an actionable submission narrative.
Health Advances delivers market access consulting for pharma and life sciences teams that need payer landscape assessment and reimbursement pathway analysis across specific countries or therapy areas. The work centers on translating payer evidence requirements into a structured evidence generation plan and a payer engagement workflow for internal and external stakeholders.
Engagement outputs are built for use in reimbursement submissions and market access launch planning, including pathway mapping and dossier-aligned evidence narratives. The strongest fit is advisory execution tied to reimbursement strategy decisions rather than broad research reporting.
- +Clear reimbursement pathway mapping tied to concrete stakeholder actions
- +Evidence generation plan outputs align with payer evidence requirements
- +Consistent synthesis of payer landscape assessment into submission-ready narrative logic
- +Direct support for payer engagement planning and KOL or advisory board workflows
- –Depth varies by geography when evidence and payer policy signals are limited
- –Requires strong client inputs on clinical data access and study artifacts
- –Automation and API surfaces are not a stated capability in engagement materials
- –Less suited to purely data-pipeline work without a consulting-led evidence build
Best for: Fits when medical, HEOR, and market access teams need consulting-led reimbursement strategy execution.
Conclusion
After evaluating 10 international markets, RTI Health Solutions stands out as our overall top pick — it scored highest across our combined criteria of features, ease of use, and value, which is why it sits at #1 in the rankings above.
Use the comparison table and detailed reviews above to validate the fit against your own requirements before committing to a tool.
How to Choose the Right market access consulting
Market access consulting for pharma teams translates payer coverage decisions into reimbursement pathway actions and dossier-ready evidence planning. This buyer guide covers RTI Health Solutions, Putnam Associates, Charles River Associates, ZS, Simon-Kucher & Partners, Deloitte, Certara, LEK Consulting, Analysis Group, and Health Advances.
The provider set spans evidence generation planning tied to payer evidence requirements, economics-first pricing strategy that feeds submission decisions, and global value dossier development across multiple submission timelines. The selection emphasizes how each firm connects payer engagement work to evidence artifacts and how much of that workflow can be automated or operationalized by internal teams.
Market access consulting for payer coverage decisions, pathway evidence planning, and dossier execution
Market access consulting supports pricing and reimbursement outcomes by mapping payer expectations to evidence generation steps, then converting those steps into submission and negotiation deliverables. Providers like RTI Health Solutions and Putnam Associates focus on evidence generation plan development that ties payer evidence requirements to draft dossier content and study concepts.
Deloitte and Certara add structured payer and HTA evidence requirement mapping that feeds an evidence generation plan built for payer and review cycles, while Charles River Associates applies economics-first reimbursement and pricing strategy reasoning to connect payer evidence needs to concrete dossier and submission decisions. For global programs, ZS emphasizes global value dossier development that aligns payer evidence requirements to dossier content across multiple submission timelines.
Market access consulting evaluation criteria for payer and dossier work
Market access consulting succeeds when payer expectations become traceable evidence inputs and then into dossier and negotiation artifacts that teams can reuse. This buyer guide focuses on that conversion chain, especially from payer evidence requirements to an evidence generation plan and structured submission content.
Evidence generation plan that ties payer requirements to dossier content
RTI Health Solutions links payer evidence requirements to draft dossier content and study concepts as a single evidence planning output. Putnam Associates traces each payer expectation to evidence gaps and dossier implications to keep submissions aligned to payer logic.
Reimbursement pathway reasoning that drives evidence and submission decisions
Charles River Associates produces economics-first reimbursement and pricing strategy outputs that connect payer evidence needs to concrete dossier and submission decisions. Analysis Group sequences reimbursement pathway analysis into a sequenced evidence generation plan for submissions that reflect payer and HTA evidence requirements.
Global dossier structuring aligned to multiple submission timelines
ZS develops global value dossier content that aligns payer evidence requirements to dossier content across multiple submission timelines. Simon-Kucher & Partners maps payer evidence requirements directly to dossier structure and produces structured value dossier materials for global and local payer contexts.
Payer and HTA evidence requirements mapping with stakeholder engagement plans
Deloitte combines payer and HTA evidence requirement mapping with a structured evidence generation plan built for payer reviews and submissions. Deloitte also supports stakeholder mapping and payer engagement planning for advocacy workflows tied to those evidence requirements.
Traceability from payer evidence logic to specific study and dossier inputs
Certara provides traceable evidence generation plan mapping that ties payer evidence requirements to specific study outputs and dossier sections. Health Advances converts payer evidence requirements into an actionable submission narrative using dossier-aligned evidence generation planning and stakeholder action mapping.
Decision framework for matching consulting delivery shape to payer and execution risk
Selection should start from how quickly teams must convert payer evidence signals into evidence generation plans and dossier-ready content. It should also consider whether internal teams can supply clinical and operational inputs on a tight review cycle for consulting-led delivery.
Choose evidence plan traceability depth when payer pathway risk is high
If payer evidence requirements must connect to both study concepts and draft dossier content, RTI Health Solutions offers that linkage as a named evidence planning deliverable. If payer expectations must be decomposed into evidence gaps with dossier implications for each expectation, Putnam Associates supports that traceability mapping.
Pick economics-first logic when pricing strategy must be decision-grade
If reimbursement and pricing strategy reasoning needs to be analytically rigorous and tied to submission decisions, Charles River Associates is built for economics-first reimbursement and pricing strategy outputs. If evidence planning also needs to reflect budget impact modeling tied to pathway assumptions, Analysis Group supports that linkage between reimbursement pathway analysis and budget impact modeling.
Select global dossier structuring when timelines span multiple payer contexts
For global programs that require evidence-led dossier alignment across multiple submission timelines, ZS builds global value dossier development tied to payer evidence requirements. For teams that want evidence requirements mapped into dossier structure with outputs usable for both global and local payer contexts, Simon-Kucher & Partners provides that end-to-end artifact linkage.
Use stakeholder and HTA evidence mapping when payer reviews intersect HTA scrutiny
If the workstream needs payer and HTA evidence requirement mapping plus stakeholder mapping and payer engagement planning, Deloitte supports a structured evidence generation plan aligned to those reviews. If payer evidence logic must be converted into an evidence plan that traces study outputs and dossier sections, Certara provides that traceable mapping workflow.
Decide based on internal input availability and preferred iteration speed
If internal access to clinical and operational inputs is limited or iteration cycles are slow, providers with consulting-led delivery like Putnam Associates, Deloitte, and ZS may still fit but require timely reviews and defined assumptions. If teams need rapid iterative workshop cycles, Charles River Associates is less optimized for workshop speed based on delivery emphasis.
Choose operating focus for evidence-to-execution handoffs
When the required deliverable is a payer-to-dossier execution narrative that coordinates stakeholder actions, Health Advances centers dossier-aligned evidence generation planning tied to those actions. When the main requirement is that evidence planning links payer evidence requirements to inputs for payer landscape and reimbursement pathway decisions, LEK Consulting emphasizes that mapping to actionable evidence generation plan outputs.
Who market access consulting is for in payer engagement and dossier execution
Market access consulting fits teams that must translate payer coverage logic into evidence planning steps and submission-ready dossier content. This set is especially relevant to pharma groups that manage multiple payers or intersect payer review with HTA scrutiny.
Pharma market access and HEOR teams responsible for payer evidence generation plans
RTI Health Solutions and Putnam Associates both focus on turning payer evidence requirements into evidence plan deliverables and dossier implications that teams can take into execution cycles.
Pricing and reimbursement strategy leads needing decision-grade economic reasoning
Charles River Associates delivers economics-first reimbursement and pricing strategy outputs tied to payer evidence needs and concrete submission decisions, which supports cross-functional alignment.
Global programs managing multiple submission timelines and payer contexts
ZS and Simon-Kucher & Partners emphasize global value dossier alignment to payer evidence requirements across timelines and across global and local payer contexts.
Medical, HEOR, and market access teams coordinating stakeholder actions for payer and review cycles
Deloitte pairs payer and HTA evidence requirement mapping with stakeholder mapping and payer engagement planning, while Health Advances centers evidence outputs that align to concrete stakeholder actions.
Teams needing traceable evidence logic from payer expectations to specific study and dossier sections
Certara emphasizes traceable evidence generation plan mapping to specific study outputs and dossier sections, which supports internal governance over evidence-to-dossier integrity.
Common failure modes when buying market access consulting services
A frequent mistake is commissioning payer mapping without a conversion path to evidence generation steps and dossier sections. That leads to work products that are hard to operationalize for submissions and negotiations.
Buying payer landscape work that stops at narrative mapping instead of producing dossier-aligned evidence plans
RTI Health Solutions and Putnam Associates connect payer evidence logic to evidence plan deliverables and dossier implications. Teams should reject engagements that do not produce traceable evidence inputs that map to draft dossier content.
Expecting self-serve automation from consulting-led providers
RTI Health Solutions and Putnam Associates are consulting-led and provide limited automation surface for self-serve teams. Teams that require API-driven automation for ongoing data refresh should treat automation depth and integration surface as a primary procurement criterion.
Starting without ensuring timely internal access to study artifacts and operational inputs
Putnam Associates and Charles River Associates depend on client-provided data and timely reviews to finalize evidence plans and submission-linked outputs. Teams should staff internal SMEs for the payer evidence assumptions review to avoid evidence-plan delays.
Confusing economics strategy depth with iterative workshop agility
Charles River Associates is not optimized for rapid, highly iterative workshop cycles, even when reimbursement strategy needs strong analytics. Teams that expect frequent workshop pivots should align timeline expectations with the provider’s delivery style.
Under-scoping the geography-dependent evidence detail needed for global dossiers
Health Advances notes depth variability by geography when evidence and payer policy signals are limited. Global programs should define the required dossier granularity per market and confirm the evidence-plan traceability expectations across those markets.
How We Selected and Ranked These Providers
We evaluated RTI Health Solutions, Putnam Associates, Charles River Associates, ZS, Simon-Kucher & Partners, Deloitte, Certara, LEK Consulting, Analysis Group, and Health Advances on features, ease, and value with features weighted at 40% and ease and value weighted at 30% each. RTI Health Solutions ranked highest because its evidence generation plan development ties payer evidence requirements to draft dossier content and study concepts, creating a clearer conversion chain from payer logic to submission-ready artifacts.
Putnam Associates ranked highly because its payer evidence requirements mapping traces each payer expectation to specific evidence gaps and dossier implications that directly shape evidence planning. ZS and Simon-Kucher & Partners ranked well for global value dossier alignment across multiple submission timelines, while Charles River Associates and Analysis Group earned points for reimbursement and pricing strategy outputs grounded in payer evidence needs and linked to submission decisions.
Frequently Asked Questions About market access consulting
Which provider work products connect payer evidence requirements to dossier sections without gaps?
How does market access consulting typically handle data migration and upstream input quality for payer pathway analysis?
When does payer engagement planning become a deliverable versus a workshop activity, and who operationalizes it best?
What breaks if internal teams expect automation-first, self-serve configuration during reimbursement pathway work?
Where do payer landscape assessment and reimbursement pathway analysis fall short if the evidence generation plan is not sequenced to submissions?
Which provider approach is strongest for global value dossier development across markets with different evidence expectations?
How do providers differ in translating coverage policy signals into formulary and reimbursement decisions?
Which service is best when the core need is reimbursement submission narrative readiness tied to payer review logic?
What tradeoff occurs when strategy-heavy market access consulting must also deliver analytic rigor?
Tools reviewed
Primary sources checked during evaluation.
Referenced in the comparison table and product reviews above.
- International MarketsTop 10 Best Financial Market Services of 2026
- Digital Transformation In IndustryTop 10 Best Access Consulting Services of 2026
- Market ResearchTop 10 Best Growth Strategy Consulting Services of 2026
- International MarketsTop 10 Best Market Access Software of 2026
- Business Process OutsourcingTop 10 Best Consulting Services Software of 2026
Keep exploring
Comparing two specific tools?
Software Alternatives
See head-to-head software comparisons with feature breakdowns, pricing, and our recommendation for each use case.
Explore software alternatives→In this category
International Markets alternatives
See side-by-side comparisons of international markets tools and pick the right one for your stack.
Compare international markets tools→